Stirling Products (ASX:STI) advises shareholders that it has terminated its relationship with West Australian company Cocky Smart Pty Ltd for the exclusive global licensing rights to their novel insecticide compound originally isolated from cockatoo feathers.
Stirling Products (ASX:STI) advises shareholders that it has received notice that its patent application for "Methods of decreasing fat deposits and body weight in mammals and birds" has been granted in New Zealand. Patent applications have been filed in a number of different countries; this represents the first successful approval.
Stirling Products (ASX:STI) advises shareholders that it launched PetQuench(tm), the first of its companion animal products, at one of Canada's largest pet shows last weekend. PetQuench(tm) was released onto the Canadian market through Stirling Animal Health at the prestigious PIJAC National Industry Trade Show in Ontario, Canada.
Stirling Products (ASX:STI) advises shareholders that it has commenced a consolidation process that will result in a dedicated subsidiary for its global sales and marketing efforts. Stirling has over the last two years undergone a growth and acquisition phase with the establishment of the Danish joint venture Pulmovet in July 2006 (ASX: July 13, 2006), the acquisition of Progressive BioActives Inc.
Stirling Products (ASX:STI) advises shareholders that it has now completed the transaction to acquire worldwide licensing rights for the product PetQuench(tm). PetQuench(tm), fortified water for dogs and cats, is already on the market in North America and is expected to be launched in Australia by the end of Q1 2009.
Stirling Products (ASX:STI) wishes to advise shareholders that its patent application for "the treatment of heaves in horses" with R-salbutamol has now been granted in Australia. The company previously announced that the patent had also been approved in South Africa (ASX, October 10, 2006).
Stirling Products North America Inc (STI-NA)(ASX:STI) has presented results of a ground-breaking study into the Loma gill disease infection of farmed fish, especially salmon and trout, at the 2008 Annual Meeting of the American Fisheries Society (FHS-AFS). The results presented demonstrate the effectiveness of Stirling's proprietary beta glucan product, ProVale(tm), in inhibiting the impact of Loma salmonae, a costly and untreatable disease in farmed fish, especially Pacific salmon.
